DailyFinance Avastin, in combination with fluropyrimidine- irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy, is indicated for the second-line treatment of ...
MedPage Today The combination of cetuximab (Erbitux) and FOLFIRI chemotherapy (5-FU, folinic acid, and irinotecan ) achieved almost a 4-month advantage over the combination of bevacizumab (Avastin) and FOLFIRI. However, patients treated with either had similar ...
PharmiWeb.com (press release) Additionally the poster presentation entitled ‚ÄúPhase II clinical activity and tolerability of the SMAC-mimetic birinapant (TL32711) plus irinotecan in irinotecan -relapsed/refractory metastatic colorectal cancer‚Äù (Abstract 3621) reported clinical ... and more »
The Oncology Report CHICAGO – The combination of bevacizumab and irinotecan far outshone tenozolomide in delaying disease progression among patients with MGMT-unmethylated glioblastoma, an investigator reported at the annual meeting of the American Society of ...
Marketwire (press release) The data, presented on June 2nd at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA, showed that CRC patients with methylated DCR1 did not benefit from the addition of irinotecan to capecitabine therapy. and more »
GlobeNewswire (press release) Both ADC product candidates involve SN-38, the active metabolite of irinotecan (used to treat metastatic colorectal and other solid cancers), conjugated by the Company's proprietary technology to labetuzumab (anti-CEACAM5 humanized monoclonal ...
MarketWatch People who received Avastin alone or Avastin plus irinotecan * (chemotherapy) experienced mild to life-threatening side effects including bleeding (occurred in 40 percent of people), nosebleeds (occurred in 26 percent of people), bleeding in the brain ...
DailyFinance People who received Avastin alone or Avastin plus irinotecan * (chemotherapy) experienced mild to life-threatening side effects including bleeding (occurre...
The Herald | HeraldOnline.com Additionally, the poster presentation entitled “Phase II clinical activity and tolerability of the SMAC-mimetic birinapant (TL32711) plus irinotecan in irinotecan -relapsed/refractory metastatic colorectal cancer” (Abstract 3621) reported clinical ... and more »
